Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242642 · ClinicalTrials.gov registry record · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
A NA study of Mitral Valve Regurgitation, sponsored by Medtronic Cardiovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 1,056
- Enrollment target
- 20
- Study locations
NCT03242642 is a NA study of Mitral Valve Regurgitation that is actively recruiting participants, run by Medtronic Cardiovascular. The registered enrollment target is 1,056 participants, above the 718-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03242642, a NA study of Mitral Valve Regurgitation, is actively recruiting participants, sponsored by Medtronic Cardiovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,056 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Conditions Studied
Interventions
- DEVICE Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Study Locations (20)
California
- Scripps Memorial Hospital - La Jolla
- PIH Health Good Samaritan Hospital - Los Angeles
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Keck Hospital of the University of Southern California, USC - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- El Camino Hospital - Mountain View
- Kaiser Permanente San Francisco Medical Center - San Francisco
- Stanford Hospital and Clinics - Stanford
- Los Robles Regional Medical Center - Thousand Oaks
Florida
- JFK Medical Center - Atlantis
- Morton Plant - Clearwater
- HealthPark Medical Center - Fort Myers
- North Florida Regional Medical Center - Gainesville
- Baptist Medical Center Jacksonville - Jacksonville
- University of South Florida - Tampa
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Alabama
- University of Alabama Birmingham (UAB) Hospital - Birmingham
Arizona
- Abrazo Heart Hospital - Phoenix
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2036-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03242642
The ClinicalTrials.gov registry entry for NCT03242642 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 718-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (47% higher). The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) is the first listed.
NCT03242642 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03242642 about?
NCT03242642 is a clinical study titled "Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.". Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
What is the current status of trial NCT03242642?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,056 participants. The study started on 2017-10-23. Estimated completion is 2036-09-30.
What conditions does trial NCT03242642 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation.
What interventions are being tested in trial NCT03242642?
The interventions under investigation include: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) (DEVICE).
Who is sponsoring clinical trial NCT03242642?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03242642 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Valve Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
RECRUITING · NA
-
AltaValve Pivotal Trial
RECRUITING · NA
-
Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System
ACTIVE NOT RECRUITING · NA
-
PARTNER 3 Trial - Mitral Valve in Valve
ACTIVE NOT RECRUITING · NA
-
MitraClip REPAIR MR Study
ACTIVE NOT RECRUITING · NA
-
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.